Amin Ariaee
Amin Ariaee is a third-year PhD candidate at the University of South Australia's Centre for Pharmaceutical Innovation (CPI), where his research focuses on novel drug delivery systems with a particular emphasis on improving gut microbiome health. His work explores the development of multifunctional therapies that address both symptoms and underlying causes of metabolic and gastrointestinal diseases.
At the core of his research is the creation of inulin-lipid microcapsules, an innovative oral drug delivery system that enhances bioavailability and promotes gut microbiota diversity. By leveraging the natural properties of inulin and lipid interactions, Amin’s work aims to improve the therapeutic efficacy of drugs, such as lurasidone, while simultaneously supporting gut health. This dual approach has significant implications for treating complex conditions related to gut microbiome imbalances.
Amin has also been exploring microbiome-sensing technologies to further optimize drug targeting within the colon. His work seeks to not only improve patient outcomes but also contribute to the evolving understanding of the gut microbiome’s role in health and disease.
Amin's expertise in formulating these advanced drug delivery systems highlights the potential for novel therapies that are both more effective and patient-friendly in managing gastrointestinal diseases.
At the core of his research is the creation of inulin-lipid microcapsules, an innovative oral drug delivery system that enhances bioavailability and promotes gut microbiota diversity. By leveraging the natural properties of inulin and lipid interactions, Amin’s work aims to improve the therapeutic efficacy of drugs, such as lurasidone, while simultaneously supporting gut health. This dual approach has significant implications for treating complex conditions related to gut microbiome imbalances.
Amin has also been exploring microbiome-sensing technologies to further optimize drug targeting within the colon. His work seeks to not only improve patient outcomes but also contribute to the evolving understanding of the gut microbiome’s role in health and disease.
Amin's expertise in formulating these advanced drug delivery systems highlights the potential for novel therapies that are both more effective and patient-friendly in managing gastrointestinal diseases.